A decision-ready blueprint
A commercial strategy and practical solution designed around the commercial realities of cell & gene therapy developers.
Scientific, commercial, and digital architecture, with specialist expertise assembled where the engagement requires it.
Cell and gene therapy developers need to connect scientific promise with the clinical, manufacturing, market-access, and partnering choices that establish a credible commercial path. The work is not a generic market report. It is a decision process that needs the right evidence, assumptions, scenarios, and review in view at the right time.
Lonrú Consulting designs the commercial strategy and practical decision tools around that work. We help teams test the questions that shape value, launch, partnering, and investment decisions, then place the approved outputs in a format leadership and functional owners can use.
We define the scientific, clinical, CMC, market, reimbursement, partner, and financial inputs relevant to the selected commercial question, including the evidence boundaries and assumptions that need to remain visible.
Configured systems can structure approved inputs, prepare comparative analysis, test defined scenarios, or surface questions for review within the agreed context.
Lonrú provides principal-led commercial strategy, decision framing, and review governance. Client scientific, clinical, manufacturing, market-access, finance, and commercial SMEs review work within their areas of accountability.
Reviewed outputs are delivered through a pricing or value model, market and partner view, decision tracker, or executive interface that supports the next commercial choice.
Define the value, market, access, and partnership questions that need to be resolved for the selected asset, modality, or development stage.
Create a controlled view of the agreed clinical, manufacturing, patient-benefit, and market assumptions that inform a pricing, reimbursement, or Net Present Value discussion.
Relate the clinical, CMC, regulatory, and market factors that influence a launch, partnering, out-licensing, or portfolio decision without treating them as isolated workstreams.
Give leadership and functional owners a reviewed interface for the current commercial question, its evidence, assumptions, open issues, and next actions.
The work can structure evidence, make assumptions explicit, and support scenario testing. It does not guarantee pricing, reimbursement, regulatory, partnering, financing, or commercial outcomes.
We establish the approved sources, review ownership, and decision rights at the outset. Scientific, clinical, legal, financial, and executive accountability remains with the appropriate client owners and governance process.
Relevant experience
NPV modelling
Designed multi-dimensional pricing and Net Present Value modelling systems for cell and gene therapies, integrating clinical-trial milestones, manufacturing COG constraints, and quantified patient-benefit metrics.
Integrated
Architected governed data pipelines and executive dashboards that connect commercial, market, and operating signals, making pipeline movement, search demand, and conversion patterns easier to inspect and act on.
Architecture in context
Diagram summary: Scientific, clinical, manufacturing, market, and commercial evidence is contextualised, analysed, and tested through ActiveArchitecture™ before it supports a Go-to-Market or partnership decision.
Practical questions
Next step
Bring the decision, workflow, or delivery constraint that needs a clearer operating path.
Request a focused briefing